 sequenti intracarotid bcnu cisplatin recurr malign glioma author patient recurr malign glioma trial sequenti intracarotid bcnu cisplatin protocol design cours bcnu dose mg cisplatin dose mg interv eight patient evalu first cours bcnu partial minor respons patient evalu first cours cisplatin evalu second cours bcnu median surviv month rang week year cerebr ocular toxic uniqu method chemotherapi administr failur clinic improv common reason remov studi high attrit rate author unabl meaning respons sequenti bcnu cisplatin clinic degre cross-resist agent human malign glioma